Abstract
Chronic obstructive pulmonary disease (COPD) is a global health problem. COPD is associated with the progressive pulmonary inflammation and destruction of lung parenchyma (emphysema) that relate to disease severity. Therefore, it is anticipated that drugs that reduce pulmonary inflammation will provide effective, disease modifying therapy for COPD. Several specific therapies are directed against the influx of inflammatory cells into the airways and lung parenchyma that occurs in COPD; these include agents directed against cytokines and chemokines. Broad-range antiinflammatory drugs are now in phase III development for COPD; they include inhibitors of phosphodiesterase 4 (PDE4). Other drugs that inhibit cell signaling include inhibitors of p38 mitogen-activated protein kinase (MAPK), nuclear factor- κB (NF-κB), HDAC2 modifiers and phosphoinositide-3-kinase (PI3K). There is also a search for inhibitors of proteinases and matrix metalloproteinases (MMPs) to prevent lung destruction and the development of emphysema. This review highlights the studies on novel or potential anti-inflammatory agents that might be considered in the development of new future therapies for COPD.
Keywords: NF-κB, MAP kinase, MMPs, cigarette smoke, cytokines, antagonists
Current Respiratory Medicine Reviews
Title: Targeting Lung Inflammation: Novel Therapies for the Treatment of COPD
Volume: 4 Issue: 1
Author(s): Irfan Rahman, Hongwei Yao and Willem I. de Boer
Affiliation:
Keywords: NF-κB, MAP kinase, MMPs, cigarette smoke, cytokines, antagonists
Abstract: Chronic obstructive pulmonary disease (COPD) is a global health problem. COPD is associated with the progressive pulmonary inflammation and destruction of lung parenchyma (emphysema) that relate to disease severity. Therefore, it is anticipated that drugs that reduce pulmonary inflammation will provide effective, disease modifying therapy for COPD. Several specific therapies are directed against the influx of inflammatory cells into the airways and lung parenchyma that occurs in COPD; these include agents directed against cytokines and chemokines. Broad-range antiinflammatory drugs are now in phase III development for COPD; they include inhibitors of phosphodiesterase 4 (PDE4). Other drugs that inhibit cell signaling include inhibitors of p38 mitogen-activated protein kinase (MAPK), nuclear factor- κB (NF-κB), HDAC2 modifiers and phosphoinositide-3-kinase (PI3K). There is also a search for inhibitors of proteinases and matrix metalloproteinases (MMPs) to prevent lung destruction and the development of emphysema. This review highlights the studies on novel or potential anti-inflammatory agents that might be considered in the development of new future therapies for COPD.
Export Options
About this article
Cite this article as:
Rahman Irfan, Yao Hongwei and de Boer I. Willem, Targeting Lung Inflammation: Novel Therapies for the Treatment of COPD, Current Respiratory Medicine Reviews 2008; 4 (1) . https://dx.doi.org/10.2174/157339808783497873
DOI https://dx.doi.org/10.2174/157339808783497873 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Acute Phase Proteins In Acute Coronary Syndrome: An up-to-date
Cardiovascular & Hematological Agents in Medicinal Chemistry Impact of High Protein Intake on Viral Load and Hematological Parameters in HIV-infected Patients
Current HIV Research Pharmacologic Treatment for Prehypertension: To Treat or Not to Treat?
Recent Patents on Cardiovascular Drug Discovery It’s Time for An Epigenomics Roadmap of Heart Failure
Current Genomics Novel Drugs Targeting the c-Ring of the F<sub>1</sub>F<sub>O</sub>-ATP Synthase
Mini-Reviews in Medicinal Chemistry Drug Treatment of Metabolic Syndrome
Current Clinical Pharmacology CD93: Recent Advances and Implications in Disease
Current Drug Targets Integrating Coronary Calcium into Risk Prediction: Current Approaches and Future Directions
Current Cardiology Reviews Development of a Novel and Robust Pharmacological Model of Okadaic Acid-induced Alzheimer’s Disease in Zebrafish
CNS & Neurological Disorders - Drug Targets Management of Prehypertension: Current Status and Future Strategies
Current Hypertension Reviews Dietary Interventions for Atopic Disorders
Current Pharmaceutical Design Antagonism by Bioactive Polyphenols Against Inflammation: A Systematic View
Inflammation & Allergy - Drug Targets (Discontinued) Nanoceuticals as an Emerging Field: Current Status and Future Prospective
Current Nutrition & Food Science Micronutrient Biofortification in Rice through New Breeding Techniques (NBTs): Bangladesh Perspective
Current Nutraceuticals The Antidiabetic Effects of The Bioactive Flavonoid (Kaempferol-3-O-β-D-6{P- Coumaroyl} Glucopyranoside) Isolated From Allium cepa
Recent Patents on Anti-Infective Drug Discovery Cardiac Morbidity in an HIV-1 Lipodystrophy Patient Cohort Expressing the TNF-α-238 G/A Single Nucleotide Gene Polymorphism
Current HIV Research SAR, QSAR and Docking of Anticancer Flavonoids and Variants: A Review
Current Topics in Medicinal Chemistry Tissue Distribution and Pharmacodynamics: A Complicated Relationship
Current Drug Metabolism MicroRNAs in the Diagnosis and Treatment of Unstable Angina
Current Topics in Medicinal Chemistry Estrogen Receptor-α: Plasma Membrane Localization and Functions
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)